Literature DB >> 25467551

Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.

Sarah L Tansley1, Neil J McHugh.   

Abstract

The idiopathic inflammatory myopathies are a heterogeneous group of disorders affecting both adults and children. Clinical features can include muscle weakness, skin disease and internal organ involvement. A large number of autoantibodies, directed against cytoplasmic or nuclear components, can now be identified in these patients and specific clinic-serological syndromes have been described. Laboratory testing to identify many of these autoantibodies is becoming easier, and here we discuss the clinical utility of autoantibodies in myositis both in terms of facilitating diagnosis, predicting disease course and informing management decisions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25467551     DOI: 10.1007/s11926-014-0464-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  63 in total

1.  Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias.

Authors:  Kizuku Watanabe; Tomohiro Handa; Kiminobu Tanizawa; Yuji Hosono; Yoshio Taguchi; Satoshi Noma; Yoichiro Kobashi; Takeshi Kubo; Kensaku Aihara; Kazuo Chin; Sonoko Nagai; Tsuneyo Mimori; Michiaki Mishima
Journal:  Respir Med       Date:  2011-04-22       Impact factor: 3.415

2.  Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients.

Authors:  Andrea Váncsa; I Csípo; J Németh; K Dévényi; L Gergely; K Dankó
Journal:  Rheumatol Int       Date:  2009-03-06       Impact factor: 2.631

Review 3.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

4.  Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Takashi Satoh; Masataka Kuwana; Yasuhiro Katsumata; Kae Takagi; Ikuko Masuda; Akiko Tochimoto; Sayumi Baba; Yuko Okamoto; Yuko Ota; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-05-23       Impact factor: 7.580

5.  Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A.

Authors:  I Kobayashi; M Yamada; Y Takahashi; N Kawamura; M Okano; Y Sakiyama; K Kobayashi
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

6.  Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.

Authors:  Yuki Ichimura; Takashi Matsushita; Yasuhito Hamaguchi; Kenzo Kaji; Minoru Hasegawa; Yoshinori Tanino; Yayoi Inokoshi; Kazuhiro Kawai; Takuro Kanekura; Maria Habuchi; Atsuyuki Igarashi; Ryosuke Sogame; Takashi Hashimoto; Tomohiro Koga; Ayako Nishino; Naoko Ishiguro; Naoki Sugimoto; Rui Aoki; Noriko Ando; Tetsuya Abe; Takashi Kanda; Masataka Kuwana; Kazuhiko Takehara; Manabu Fujimoto
Journal:  Ann Rheum Dis       Date:  2012-01-17       Impact factor: 19.103

7.  Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis.

Authors:  H Gunawardena; L R Wedderburn; J North; Z Betteridge; J Dunphy; H Chinoy; J E Davidson; R G Cooper; N J McHugh
Journal:  Rheumatology (Oxford)       Date:  2008-01-30       Impact factor: 7.580

8.  Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.

Authors:  Z E Betteridge; H Gunawardena; H Chinoy; J North; W E R Ollier; R G Cooper; N J McHugh
Journal:  Ann Rheum Dis       Date:  2008-10-17       Impact factor: 19.103

9.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154

10.  A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.

Authors:  Stefen Brady; Waney Squier; Caroline Sewry; Michael Hanna; David Hilton-Jones; Janice L Holton
Journal:  BMJ Open       Date:  2014-04-28       Impact factor: 2.692

View more
  9 in total

Review 1.  Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

2.  The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Sara Faghihi-Kashani; Terrence P O'Hanlon; Willy A Flegel; Sharon D Adams; Ira N Targoff; Chester V Oddis; Steven R Ytterberg; Rohit Aggarwal; Lisa Christopher-Stine; Ejaz A Shamim; Paul F Dellaripa; Sonye K Danoff; Andrew L Mammen; Frederick W Miller
Journal:  Semin Arthritis Rheum       Date:  2018-02-14       Impact factor: 5.532

Review 3.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

4.  [Myositis-specific antibodies associated with juvenile dermatomyositis].

Authors:  K Eising; J Peitz; N Unterwalder; C Meisel; G Horneff
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

5.  Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study.

Authors:  Jessica F Boehler; Marshall W Hogarth; Matthew D Barberio; James S Novak; Svetlana Ghimbovschi; Kristy J Brown; Li Alemo Munters; Ingela Loell; Yi-Wen Chen; Heather Gordish-Dressman; Helene Alexanderson; Ingrid E Lundberg; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

6.  CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α.

Authors:  Christopher J M Piper; Meredyth G Ll Wilkinson; Claire T Deakin; Georg W Otto; Stefanie Dowle; Chantal L Duurland; Stuart Adams; Emiliano Marasco; Elizabeth C Rosser; Anna Radziszewska; Rita Carsetti; Yiannis Ioannou; Philip L Beales; Daniel Kelberman; David A Isenberg; Claudia Mauri; Kiran Nistala; Lucy R Wedderburn
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 7.  MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations.

Authors:  Anna Radice; Boaz Palterer; Paola Parronchi; Francesco Liotta; Cristina Scaletti
Journal:  Clin Mol Allergy       Date:  2015-11-09

Review 8.  Consensus-based recommendations for the management of juvenile dermatomyositis.

Authors:  Felicitas Bellutti Enders; Brigitte Bader-Meunier; Eileen Baildam; Tamas Constantin; Pavla Dolezalova; Brian M Feldman; Pekka Lahdenne; Bo Magnusson; Kiran Nistala; Seza Ozen; Clarissa Pilkington; Angelo Ravelli; Ricardo Russo; Yosef Uziel; Marco van Brussel; Janjaap van der Net; Sebastiaan Vastert; Lucy R Wedderburn; Nicolaas Wulffraat; Liza J McCann; Annet van Royen-Kerkhof
Journal:  Ann Rheum Dis       Date:  2016-08-11       Impact factor: 19.103

9.  Using autoantibody signatures to define cancer risk in dermatomyositis.

Authors:  Jessica L Turnier; J Michelle Kahlenberg
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.